Clinical trials · New York
Major Depressive Disorder clinical trials in New York
We’re tracking 57 recruiting major depressive disorder studies with a site in New York — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07610473RecruitingPhase 2
Testing DT-101 as an add-on for depression
This trial tests if a new medication, DT-101, can help when added to your current depression treatment. It's for adults with recurrent depression who may need extra support.
New York, New YorkAges 18–75 - NCT06911112RecruitingPhase 3
A new pill for depression when current treatment isn't working well enough
This trial tests an investigational medication (NBI-1065845) added to your current antidepressant to see if it can improve depressive symptoms. It is for people with moderate to severe depression who have not fully responded to their current antidepressant.
New York, New YorkAges 18 years+ - NCT07251491RecruitingPhase 1/Phase 2
Psilocybin for depression after spinal cord injury
This trial tests whether psilocybin (a substance found in certain mushrooms) can help treat depression in people with a spinal cord injury. You would receive the study drug in a controlled setting, and your progress would be monitored closely.
The Bronx, New YorkAges 22 years+ - NCT06963021RecruitingPhase 3
Study of NBI-1065845 for depression that hasn't fully responded to treatment
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
Cedarhurst, New YorkAges 18 years+ - NCT07592689RecruitingPhase 3
DT120 Treatment for Major Depression
This study tests whether a new medication called DT120 can help people with moderate-to-severe depression feel better. You'd take the medication for several weeks while doctors track your mood and symptoms.
New York, New YorkAges 18–74 - NCT07412756RecruitingPhase 3
Brenipatide for major depressive disorder
This trial tests a new medication, Brenipatide, to see if it helps people with major depression who are already on a stable treatment. You would need to inject the study drug yourself and complete questionnaires.
New York, New YorkAges 18–75 - NCT07284667RecruitingPhase 2
A new medicine for depression that hasn't improved with other treatments
This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.
Brooklyn, New YorkAges 18–65 - NCT06752759RecruitingPhase 3
Ketamine mist for depression
This trial tests if a ketamine mist you breathe in can help treat moderate to severe depression. It is for adults who are not helped enough by other treatments.
Brooklyn, New YorkAges 18–88 - NCT06835855Recruiting
Does mother’s depression affect baby’s attention to emotions?
This study looks at how babies of mothers with depression pay attention to emotional faces. Researchers want to learn if these babies show different patterns of attention to happy or sad cues, which could help understand early development.
Binghamton, New YorkAges 6 months+ - NCT06775379RecruitingPhase 3
Azetukalner vs. placebo for major depression
This trial tests an investigational medication called Azetukalner against a placebo to see if it helps reduce symptoms of major depressive disorder. You may qualify if you are currently in a depressive episode that started in adulthood and have not tried or failed only a few antidepressants.
Brooklyn, New YorkAges 18–74 - NCT07076407RecruitingPhase 3
Testing a new antidepressant pill for depression
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
Mount Kisco, New YorkAges 18–74 - NCT06922110Enrolling by invitationPhase 3
Long-term study of azetukalner for depression
This study is for people who already completed a previous trial of azetukalner for major depressive disorder. It tests the long-term safety and effects of continuing the medication.
Brooklyn, New YorkAges 18 years+ - NCT07573176RecruitingPhase 3
Seltorexant for Depression in Adults and Older Adults
This study tests a new medication called seltorexant as a standalone treatment for major depression. The trial is for adults and older adults who have depression that hasn't improved with other antidepressants or who haven't tried them yet.
Brooklyn, New YorkAges 18–74 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Cedarhurst, New YorkAges 18 years+ - NCT07196501RecruitingPhase 3
Study of a new add-on treatment for depression maintenance
This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.
Glen Oaks, New YorkAges 18 years+ - NCT05850689RecruitingPhase 3
Lumateperone add-on for major depression that didn’t improve
This study tests whether adding lumateperone to an antidepressant helps adults with major depressive disorder (MDD) who haven’t improved enough after trying at least two different antidepressants. It may help reduce depressive symptoms more than antidepressants alone.
Brooklyn, New YorkAges 18–65 - NCT04041479RecruitingPhase 3
Brain-scan guided rTMS for treatment-resistant depression
This trial tests whether using brain-related “biomarkers” from your scans to guide rTMS can improve depression that hasn’t responded to at least one antidepressant. It may help by targeting brain circuits linked to depression more precisely.
New York, New YorkAges 22–65 - NCT07161700Enrolling by invitationPhase 2
Long-term safety study of SPT-300 for major depression
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
Brooklyn, New YorkAges 18–66 - NCT07065240RecruitingPhase 2
Study of SPT-300 for major depression with or without anxiety
This trial tests an experimental oral medication, SPT-300, for people with major depressive disorder, even if they also have mild anxiety. The goal is to see if it helps improve mood safely.
Brooklyn, New YorkAges 18–65 - NCT05239780Recruiting
Brain stimulation study for adults with depression
This study uses an invasive approach (placement of brain monitoring/stimulation) to better understand how the brain processes reward in depression. It may help researchers develop more targeted treatments in the future.
New York, New YorkAges 18–80 - NCT05573074Recruiting
Light treatment trial for brain blood flow in depression
This study tests whether shining near-infrared light through the head can change brain blood flow and reduce depression symptoms. If you have major depression, you may be offered a non-drug, device-based approach to see how well it helps.
Orangeburg, New YorkAges 18–65 - NCT05757791RecruitingPhase 2
Testing an SGLT2 diabetes drug for depression
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
New York, New YorkAges 18–65 - NCT05773755Recruiting
Brain stimulation surgery for treatment-resistant depression
This trial studies whether deep brain stimulation (DBS)—a surgically placed brain device—can reduce severe, long-lasting depression that hasn’t responded to many treatments. It may help people whose depression has persisted despite trying multiple antidepressant and other evidence-based therapies.
New York, New YorkAges 25–70 - NCT05800925Recruiting
Triage survey to check who can join psychiatry research
This study uses a short questionnaire to figure out who is eligible to join future psychiatry research. It may help people get routed into studies that match their situation and safety needs.
New York, New YorkAges 18 years+
Major Depressive Disorder trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting major depressive disorder studies listed above.
- Integrative Clinical Trials · 4 studies
- Neurocrine Clinical Site · 4 studies
- Adams Clinical Harlem · 3 studies
- Bioscience Research · 3 studies
- Fieve Clinical Research, Inc · 3 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- IMA Clinical Research Manhattan · 2 studies
- Manhattan Behavioral Medicine · 2 studies
What taking part in a major depressive disorder study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Major Depressive Disorder trials in other states
Common questions
- Are there major depressive disorder clinical trials in New York?
- Yes. We're currently tracking 57 recruiting major depressive disorder studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a major depressive disorder study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a major depressive disorder trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New major depressive disorder studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.